Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eifRCfbwoceZnVjleXvW

  ADVERTISEMENT  
January 23, 2013News for the transfusion medicine and cellular therapy community

  Top Story 
 
  • New method shows promise for treating DVT
    Treating deep venous thrombosis with anti-clotting drugs that are delivered directly through a catheter to sites with thromboli dissolved the clots in 95% of cases and prevented rethrombosis in most patients, according to a study presented at an endovascular therapy meeting. The rate of bleeding complications was similar to that of standard DVT therapy. A larger study is being prepared to test the new treatment further, with results expected in 2016 or 2017. CardiovascularBusiness.com (1/21) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
How much do you hate your anti-Fyb?
Tired of sub-par reactions? Quotient has a newly approved anti-Fyb, as well as hard-to-find Anti-s, Anti-Wra and other rare antisera that are worth a try. Find out how the one company focused on manual testing can serve you in 2013 and beyond.

  Science & Health 
  • Study: Tattoos raise risk of hepatitis C infection
    People with one or more tattoos were more likely to have hepatitis C, independent of other risk factors, according to a study published in Hepatology that assessed the records of 3,871 participants. Doctors should be ready to educate patients about blood-borne diseases and hepatitis C testing, a researcher said. Healio (1/22) LinkedInFacebookTwitterEmail this Story
  Emerging Trends 
  Industry News & Practice 
  • Opinion: Rigorous clinical trials improve stem cell safety
    FDA oversight and requirements for rigorous clinical trials will help ensure future stem cell therapies are safe and effective, which will in turn help research organizations develop more therapies, writes Aastrom Biosciences interim CEO Dan Orlando. The FDA has already developed streamlined approval processes for breakthrough and critical drugs, and clinical investigators should engage regulators and industry to further simplify the process, Orlando writes. The Scientist online (1/21) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  • FDA OKs InfraScan's updated device to identify brain bleeding
    The FDA has granted InfraScan approval for the next generation of its Infrascanner, which uses near-infrared technology to allow for the noninvasive detection of bleeding in the brain. The newly approved device, called the Infrascanner Model 2000, was created in collaboration with the U.S. Marine Corps and Navy and has military specifications. It also could be used in sports medicine and other areas. MassDevice.com (Boston) (1/21) LinkedInFacebookTwitterEmail this Story
  Association News 
  • Reminder: AABB requests nominations for 2013, 2014 memorial awards
    AABB is seeking nominations for its 2013 and 2014 memorial awards, which will honor individuals who have advanced the practice of transfusion medicine and cellular therapies. The awards are presented to recognize achievements in administration, immunohematology, quality and innovative research, and overall outstanding service. Individuals are encouraged to nominate candidates by completing and submitting the online nomination form by this Friday, Jan. 25. Recipients will be honored at the 2013 AABB Annual Meeting in Denver or the 2014 AABB Annual Meeting in Philadelphia. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
BLOOD BANK PROFESSIONALSHealthCare Connections, Inc.US - Nationwide
CTS Director Technical Training and Document SystemsCTS US - AZ - Tempe
Performance Improvement ConsultantBlood Systems, Inc.US - AZ - Scottsdale
Director of Quality SystemsRock River Valley Blood CenterUS - IL - Rockford
Clinical Lab Specialist IICreative Testing SolutionsUS - FL - St. Petersburg
Click here to view more job listings.

  SmartQuote 
Lend yourself to others, but give yourself to yourself."
--Michel de Montaigne,
French writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information